Participants in the REWIND trial achieved a significant reduction in total cardiovascular disease burden with dulaglutide versus placebo, report the investigators.
Dulaglutide doses of 3.0 and 4.5 mg are significantly more efficacious than the standard doses, with similar safety profiles, report the AWARD 11 investigators.
Dulaglutide is associated with better treatment persistence and lower rates of treatment modification versus other glucagon-like peptide‑1 receptor agonists in people with type 2 diabetes, suggests a study of Swedish health registries.
Editorial Board member Sanjay Kalra presents a pragmatic approach to the use of glucagon-like peptide-1 receptor agonists in patients affected by acute myocardial infarction.
How will the findings of the REWIND trial and the DECLARE-TIMI 58 renal outcomes analysis affect treatment decisions for high-risk diabetes patients without overt cardiovascular disease? medwireNews asks Kamlesh Khunti.
With four GLP-1 receptor agonists now having published cardiovascular outcome data, medwireNews takes a look at how the experts are interpreting the conflicting findings, and what they mean for prescribing decisions.